RCUSArcus Biosciences Inc

Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced a clinical trial collaboration and supply agreement with...

Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer and inflammatory and autoimmune diseases, announced that its management team will participate in a fireside chat at the...

Arcus Biosciences (NYSE:RCUS - Get Free Report) posted its earnings results on Tuesday. The company reported ($1.02) EPS for the quarter, missing the consensus estimate of ($0.92) by ($0.10). Arcus...

Arcus Biosciences (RCUS) delivered earnings and revenue surprises of -10.87% and +21.43%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and...

Truist Financial raised Arcus Biosciences to a "strong-buy" rating in a report on Monday...

Eton Pharmaceuticals (ETON) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Apellis Pharmaceuticals (APLS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Arcus Biosciences (NYSE:RCUS) will be releasing its Q1 2026 earnings after the market closes on Tuesday, May 5. (View Earnings Report at...